scholarly journals Gut microbiota – a new companion on the path of cardiovascular diseases progression: surprising roles of long-time neighbors

2016 ◽  
Vol 12 (1) ◽  
pp. 66-71 ◽  
Author(s):  
O. M. Drapkina ◽  
A. N. Kaburova
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Long Time

scholarly journals Association Between Frailty and Gut Microbiota Metabolite TMAO in Older People With Cardiovascular Disease

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 210-211
Author(s):  
Wei He ◽  
Hua Wang ◽  
Jiefu Yang
Keyword(s):  
Older Adults ◽  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Linear Trend ◽  
Frailty Index ◽  
Concentration Data ◽  
Dependent Relationship ◽  
The Status ◽  
Cubic Spline Curve ◽  
The Relationship

Abstract The potential for the gut microbiota to affect health has particular relevance for older adults. Recent evidence suggests that microbiota-derived metabolites may modulate aging-related changes in immunity, sarcopenia, and cognitive function, all of which are elements of frailty. Trimethylamine N-oxide (TMAO) produced by the metaorganismal metabolism of choline, has been implicated in disease pathogenesis. However, relatively little geroscience research has been carried out on TMAO，and even less on other gut microbiota metabolites. The purpose of this study was to explore the relationship between frailty and circulating TMAO concentration. Data and fasting blood samples came from a prospective comprehensive geriatric assessment cohort of older adults (age≥65, n=451) with cardiovascular diseases. The frailty index based on the accumulated deficits model (48 variables) was used for evaluating the status of frailty. TMAO levels differed between groups with a significant increase for people with frailty (p＜0.001). Compared with the lowest quartile of TMAO levels, patients in the highest quartile had increased 3.07-fold risk of frailty (OR=3.07, 95%CI, 1.69-2.97). After adjusting for age, gender, BMI, history of diseases, hsCRP, LDLc, TMAO levels remained associated with frailty (OR=2.11, 95%CI, 1.01-4.38). Similarly, a cubic spline curve showed a dose-dependent relationship between the odds ratio for the risk of frailty and circulating TMAO in a linear trend (p = 0.006). This study suggests that circulating TMAO are independently associated with frailty in older adult with cardiovascular diseases. Efforts to further characterize the relationship between gut microbiota metabolite and frailty should be further pursued.

scholarly journals The Emerging Role of Gut Microbiota in Cardiovascular Diseases

2021 ◽  
Author(s):  
Dilip Kumar ◽  
Sanjeev S. Mukherjee ◽  
Rabin Chakraborty ◽  
Rana Rathod Roy ◽  
Arindam Pandey ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota

scholarly journals Gut Microbiota Changes in Nonalcoholic Fatty Liver Disease and Concomitant Cardiovascular Diseases

2020 ◽  
Author(s):  
Olena H. Kurinna
Keyword(s):  
Liver Disease ◽  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Statistical Significance ◽  
Microbiota Composition ◽  
Nonalcoholic Fatty Liver ◽  
Gut Microbiota Composition

AbstractNonalcoholic fatty liver disease (NAFLD) bears serious economic consequences for the health care system worldwide and Ukraine, in particular. Cardiovascular diseases (CVD) are the main cause of mortality in NAFLD patients. Changes in the gut microbiota composition can be regarded as a potential mechanism of CVD in NAFLD patients.The purpose of this work was to investigate changes in major gut microbiota phylotypes, Bacteroidetes, Firmicutes and Actinobacteria with quantification of Firmicutes/Bacteroidetes in NAFLD patients with concomitant CVD.The author enrolled 120 NAFLD subjects (25 with concomitant arterial hypertension (AH) and 24 with coronary artery disease (CAD)). The gut microbiota composition was assessed by qPCR.Resultsthe author found a marked tendency towards an increase in the concentration of Bacteroidetes (by 37.11% and 21.30%, respectively) with a decrease in Firmicutes (by 7.38% and 7.77%, respectively) in both groups with comorbid CAD and AH with the identified changes not reaching a statistical significance. The author quantified a statistically significant decrease in the concentration of Actinobacteria in patients with NAFLD with concomitant CAD at 41.37% (p<0.05) as compared with those with an isolated NAFLD. In patients with concomitant AH, the content of Actinobacteria dropped by 12.35%, which was statistically insignificant.Conclusionsthe author established changes in the intestinal microbiota, namely decrease in Actinobacteria in patients with CAD, which requires further research.

scholarly journals From obesity through gut microbiota to cardiovascular diseases: a dangerous journey

2020 ◽  
Vol 10 (1) ◽  
pp. 35-49 ◽  
Author(s):  
Paolo Marzullo ◽  
◽  
Laura Di Renzo ◽  
Gabriella Pugliese ◽  
Martina De Siena ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota

scholarly journals ROLE OF GUT MICROBIOTA IN LIPID METABOLISM

2018 ◽  
Vol 11 (4) ◽  
pp. 4 ◽  
Author(s):  
Khrystyna Kvit ◽  
Viacheslav Kharchenko
Keyword(s):  
Lipid Metabolism ◽  
Gut Microbiota ◽  
Intestinal Microbiota ◽  
Blood Lipids ◽  
Published Data ◽  
Long Time ◽  
Lipid Balance ◽  
The Relationship

 Researchers have studied the connection between cholesterol and microbiota for a long time. The results of widely published data demonstrate that the relationship between the lipid balance of the blood and the composition of the intestinal microbiota is apparent. The oblective of this study was, we tried to find the path through which this connection is carried out. Furthermore, the aim was to analyze the studies, which demonstrate the decrease of blood lipids as the result of different prebiotics and probiotics prescribtion. Also, the screening of different data from previous years was done for comparing the changes in the pathogenesis.

scholarly journals Short chain fatty acids and methylamines produced by gut microbiota as mediators and markers in the circulatory system

2020 ◽  
Vol 245 (2) ◽  
pp. 166-175 ◽  
Author(s):  
Maksymilian Onyszkiewicz ◽  
Kinga Jaworska ◽  
Marcin Ufnal
Keyword(s):  
Fatty Acids ◽  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Therapeutic Targets ◽  
Circulatory System ◽  
Short Chain Fatty Acids ◽  
Short Chain ◽  
Bacterial Strains ◽  
Ample Evidence ◽  
Chain Fatty Acids

Ample evidence suggests that gut microbiota-derived products affect the circulatory system functions. For instance, short chain fatty acids, that are the products of dietary fiber bacterial fermentation, have been found to dilate blood vessels and lower blood pressure. Trimethylamine, a gut bacteria metabolite of carnitine and choline, has recently emerged as a potentially toxic molecule for the circulatory system. To enter the bloodstream, microbiota products cross the gut–blood barrier, a multilayer system of the intestinal wall. Notably, experimental and clinical studies show that cardiovascular diseases may compromise function of the gut–blood barrier and increase gut-to-blood penetration of microbiota-derived molecules. Hence, the bacteria products and the gut–blood barrier may be potential diagnostic and therapeutic targets in cardiovascular diseases. In this paper, we review research on the cardiovascular effects of microbiota-produced short chain fatty acids and methylamines. Impact statement Despite a progress in the diagnosis and treatment of cardiovascular diseases, there are still significant gaps in understanding complex mechanisms underlying cardiovascular pathology. Increasing evidence suggests that gut microbiota products such as short chain fatty acids or methylamines may affect the circulatory system in health and disease. Hence, the microbiota-derived molecules are potential diagnostic and therapeutic targets in cardiovascular diseases. Therapeutic options may include administration of selected bacterial strains (probiotics) producing desired metabolites or administration of direct gut microbiota products.

scholarly journals Use of Exogenous and Endogenous Photomediators as Efficient ROS Modulation Tools: Results and Perspectives for Therapeutic Purposes

2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
Maria Rosa Antognazza ◽  
Ilaria Abdel Aziz ◽  
Francesco Lodola
Keyword(s):  
Oxidative Stress ◽  
Reactive Oxygen Species ◽  
Cardiovascular Diseases ◽  
Fluorescent Probes ◽  
State Of The Art ◽  
Polymeric Materials ◽  
Living Systems ◽  
Oxygen Species ◽  
Recent Developments ◽  
Long Time

Reactive Oxygen Species (ROS) play an essential dual role in living systems. Healthy levels of ROS modulate several signaling pathways, but at the same time, when they exceed normal physiological amounts, they work in the opposite direction, playing pivotal functions in the pathophysiology of multiple severe medical conditions (i.e., cancer, diabetes, neurodegenerative and cardiovascular diseases, and aging). Therefore, the research for methods to detect their levels via light-sensitive fluorescent probes has been extensively studied over the years. However, this is not the only link between light and ROS. In fact, the modulation of ROS mediated by light has been exploited already for a long time. In this review, we report the state of the art, as well as recent developments, in the field of photostimulation of oxidative stress, from photobiomodulation (PBM) mediated by naturally expressed light-sensitive proteins to the most recent optogenetic approaches, and finally, we describe the main methods of exogenous stimulation, in particular highlighting the new insights based on optically driven ROS modulation mediated by polymeric materials.

The gut microbiota and cardiovascular diseases

2018 ◽  
Vol 30 (1) ◽  
pp. 26-32
Author(s):  
Caroline Chong-Nguyen ◽  
Henri Duboc ◽  
Harry Sokol
Keyword(s):  
Cardiovascular Diseases ◽  
Gut Microbiota

scholarly journals Gut Microbiota and Response to Immunotherapeutic Drugs in Oncology: More Questions Than Answers

2020 ◽  
Vol 14 ◽  
pp. 117955492093386
Author(s):  
Dhiraj Abhyankar ◽  
Kelly T McKee ◽  
Pavle Vukojevic
Keyword(s):  
Gut Microbiota ◽  
Gut Microbiome ◽  
Clinical Evidence ◽  
Response Rate ◽  
Clinical Use ◽  
Patients With Cancer ◽  
Long Time ◽  
Gut Microorganisms

Immuno-oncology drugs (IODs) have revolutionized the treatment of some cancers. Although IODs are enabling some patients with cancer to become long-time survivors, only 30% to 40% respond to these drugs. There is experimental and clinical evidence that the gut microbiome may play a role in IOD response, leading to speculation that manipulation of the gut microenvironment might improve the response rate to IODs. We review the evidence relating to how gut microorganisms may affect response to IODs and discuss the implications of targeting the microbiome to improve IOD response, including the challenges to refine and translate the findings to practical clinical use.

scholarly journals Gut Microbiota: An Important Link between Western Diet and Chronic Diseases

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2287 ◽  
Author(s):  
Zumin Shi
Keyword(s):  
Risk Factor ◽  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Chronic Diseases ◽  
Western Diet ◽  
Processed Food ◽  
High Intake ◽  
Important Link

A Western diet characterised by high intake of energy-dense and processed food is a risk factor for many chronic diseases including diabetes, obesity and cardiovascular diseases [...]

Sign in / Sign up

Export Citation Format

Share Document